- Home
- BMRN vs VCEL Comparison
BMRN vs VCEL Comparison
Compare BMRN & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRN
- VCEL
- Stock Information
- Founded
- BMRN 1996
- VCEL 1989
- Country
- BMRN United States
- VCEL United States
- Employees
- BMRN N/A
- VCEL N/A
- Industry
- BMRN Biotechnology: Pharmaceutical Preparations
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BMRN Health Care
- VCEL Health Care
- Exchange
- BMRN Nasdaq
- VCEL Nasdaq
- Market Cap
- BMRN 13.7B
- VCEL N/A
- IPO Year
- BMRN 1999
- VCEL 1997
- Fundamental
- Price
- BMRN $70.52
- VCEL $46.26
- Analyst Decision
- BMRN Buy
- VCEL Strong Buy
- Analyst Count
- BMRN 22
- VCEL 8
- Target Price
- BMRN $94.00
- VCEL $63.00
- AVG Volume (30 Days)
- BMRN 1.6M
- VCEL 432.9K
- Earning Date
- BMRN 04-23-2025
- VCEL 05-07-2025
- Dividend Yield
- BMRN N/A
- VCEL N/A
- EPS Growth
- BMRN 153.71
- VCEL N/A
- EPS
- BMRN 2.21
- VCEL 0.20
- Revenue
- BMRN $2,853,915,000.00
- VCEL $237,224,000.00
- Revenue This Year
- BMRN $12.23
- VCEL $23.23
- Revenue Next Year
- BMRN $9.90
- VCEL $24.41
- P/E Ratio
- BMRN $31.97
- VCEL $229.93
- Revenue Growth
- BMRN 17.97
- VCEL 20.10
- 52 Week Low
- BMRN $60.63
- VCEL $39.12
- 52 Week High
- BMRN $94.85
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- BMRN 59.12
- VCEL 33.23
- Support Level
- BMRN $69.89
- VCEL $47.08
- Resistance Level
- BMRN $73.51
- VCEL $52.06
- Average True Range (ATR)
- BMRN 2.04
- VCEL 2.82
- MACD
- BMRN 0.16
- VCEL -0.39
- Stochastic Oscillator
- BMRN 52.81
- VCEL 8.78
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.